Moderna reports Covid vaccine, in trial at SLU, is 95% effective, can be stored at higher temperatures

The Massachusetts-based biotech firm says an early look at data from its Covid-19 vaccine's phase 3 trial, in which Saint Louis University is participating, shows it may be more effective than Pfizer’s leading candidate at preventing infection and will be easier to distribute.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.